doi: 10.1111/j.1365-2125.1984.tb02571.x.
Domperidone and levodopa in Parkinson's disease
- PMID:6529536
- PMCID: PMC1463696
- DOI: 10.1111/j.1365-2125.1984.tb02571.x
Item in Clipboard
Domperidone and levodopa in Parkinson's disease
J S Shindler et al. Br J Clin Pharmacol.1984 Dec.
Display options
Format
Display options
Format
Abstract
To study the absorption of levodopa and interaction with the extracerebral dopamine antagonist domperidone, 15 patients with idiopathic Parkinson's disease were given levodopa 500 mg p.o., alone, and with domperidone pre-treatment. Domperidone pretreatment (10, 20, 40 mg, p.o., i.v. or i.m.) caused a mean 12% increase in peak plasma levodopa concentration, which occurred a mean of 10 min earlier than when levodopa was given alone. Parkinsonian disability scores were improved and peak clinical response occurred 16 min earlier with domperidone than without. Domperidone slightly increases the immediate bioavailability (over 4 h) and anti-parkinsonian response to a given dose of levodopa.
Similar articles
- Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease.Nishikawa N, Nagai M, Tsujii T, Iwaki H, Yabe H, Nomoto M.Nishikawa N, et al.Clin Neuropharmacol. 2012 Jul-Aug;35(4):182-4. doi: 10.1097/WNF.0b013e3182575cdb.Clin Neuropharmacol. 2012.PMID:22751085Clinical Trial.
- Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.Langdon N, Malcolm PN, Parkes JD.Langdon N, et al.Clin Neuropharmacol. 1986;9(5):440-7. doi: 10.1097/00002826-198610000-00004.Clin Neuropharmacol. 1986.PMID:3768866
- DA-9701 on gastric motility in patients with Parkinson's disease: A randomized controlled trial.Shin CM, Lee YJ, Kim JM, Lee JY, Kim KJ, Choi YJ, Kim N, Lee DH.Shin CM, et al.Parkinsonism Relat Disord. 2018 Sep;54:84-89. doi: 10.1016/j.parkreldis.2018.04.018. Epub 2018 Apr 21.Parkinsonism Relat Disord. 2018.PMID:29705555Clinical Trial.
- Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS.Brogden RN, et al.Drugs. 1982 Nov;24(5):360-400. doi: 10.2165/00003495-198224050-00002.Drugs. 1982.PMID:6756878Review.
- [Use of apomorphine in the treatment of Parkinson's disease].Pollak P, Gervason CL.Pollak P, et al.Presse Med. 1991 Sep 21;20(29):1361-4.Presse Med. 1991.PMID:1835009Review.French.No abstract available.
Cited by
- Domperidone.Critchley P, Langdon N, Parkes JD, Quinn NP, Shindler JS, Marsden CD.Critchley P, et al.Br Med J (Clin Res Ed). 1985 Mar 9;290(6470):788. doi: 10.1136/bmj.290.6470.788-b.Br Med J (Clin Res Ed). 1985.PMID:3918756Free PMC article.No abstract available.
- Domperidone.Bateman DN.Bateman DN.Br Med J (Clin Res Ed). 1985 Apr 6;290(6474):1079. doi: 10.1136/bmj.290.6474.1079-a.Br Med J (Clin Res Ed). 1985.PMID:3921116Free PMC article.No abstract available.
- Bladder and bowel dysfunction in Parkinson's disease.Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T.Sakakibara R, et al.J Neural Transm (Vienna). 2008;115(3):443-60. doi: 10.1007/s00702-007-0855-9. Epub 2008 Mar 10.J Neural Transm (Vienna). 2008.PMID:18327532Review.
- Antiparkinsonian agents. Drug interactions of clinical significance.Pfeiffer RF.Pfeiffer RF.Drug Saf. 1996 May;14(5):343-54. doi: 10.2165/00002018-199614050-00006.Drug Saf. 1996.PMID:8800629Review.
- The effects of domperidone on the absorption of levodopa in normal subjects.Bradbrook ID, Gillies HC, Morrison PJ, Rogers HJ.Bradbrook ID, et al.Eur J Clin Pharmacol. 1986;29(6):721-3. doi: 10.1007/BF00615966.Eur J Clin Pharmacol. 1986.PMID:3709616
References
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical